Brookstone Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$818K Sell
7,408
-3,624
-33% -$350K 0.01% 769
2026
Q2
$863K Buy
+11,032
New +$752K 0.01% 746
2025
Q2
– Sell
-61,601
Closed -$3.93M – 1079
2025
Q1
$3.93M Buy
61,601
+1,014
+2% +$58.9K 0.06% 307
2024
Q4
$2.9M Hold
60,587
– – 0.04% 324
2024
Q3
$3.47M Sell
60,587
-1,110
-2% -$63.6K 0.05% 303
2024
Q2
$3.38M Sell
61,697
-13
-0% -$570 0.06% 293
2024
Q1
$2.51M Buy
61,710
+1,402
+2% +$52.6K 0.04% 325
2023
Q4
$2.23M Sell
60,308
-28
-0% -$1.06K 0.04% 312
2023
Q3
$2.16M Sell
60,336
-79
-0.1% -$3.24K 0.05% 292
2023
Q2
$2.21M Hold
60,415
– – 0.04% 294
2023
Q1
$2.17M Buy
60,415
+105
+0.2% +$4.92K 0.04% 308
2022
Q4
$3.35M Hold
60,310
– – 0.07% 221
2022
Q3
$2.57M Sell
60,310
-35
-0.1% -$1.55K 0.06% 244
2022
Q2
$3.12M Buy
60,345
+35
+0.1% +$1.51K 0.07% 225
2022
Q1
$2.5M Hold
60,310
– – 0.05% 260
2021
Q4
$2.25M Hold
60,310
– – 0.04% 253
2021
Q3
$2.22M Hold
60,310
– – 0.04% 255
2021
Q2
$2.71M Buy
+60,310
New +$2.67M 0.05% 226

Other funds holding HALO

Brookstone Capital Management's HALO Position: Q3 2026 in Review

Brookstone Capital Management reduced its Halozyme (HALO) stake by 33% in Q3 2026, selling an estimated $350K and leaving 7,408 shares worth $818K. The position accounts for 0.01% of the portfolio, ranked #769.

Brookstone Capital Management first reported a position in HALO in Q2 2021 and has held it in 18 quarters since. The position peaked at $3.93M in Q1 2025. 774 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Brookstone Capital Management held 7,408 shares of Halozyme worth $818K as of Q3 2026.
  • Brookstone Capital Management sold 3,624 Halozyme shares in Q3 2026, an estimated $350K.
  • Halozyme made up 0.01% of Brookstone Capital Management's portfolio in Q3 2026, its #769 holding.
  • Brookstone Capital Management first reported a position in Halozyme in Q2 2021 and has held it in 18 quarters since.
  • Brookstone Capital Management's Halozyme position peaked at $3.93M in Q1 2025.
  • 774 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Brookstone Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.